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 Abstract 
 The recently recognized higher prevalence of 
pituitary tumours presents a challenge for 
endocrinologists and health-care resource pro-
viders in terms of diagnostics and therapy. The 
majority of pituitary tumors arise sporadically 
as anterior pituitary adenomas but approxi-
mately 5% can be attributed to a familial syn-
drome. The clinical and genetic characteristics 
of familial pituitary adenomas have been well 
portrayed in multiple endocrine neoplasia type 
1 (MEN 1) and Carney complex (CNC). 
Recently, familial cases of pituitary tumours 
that were unrelated to MEN 1 or CNC were 
described under the clinical de fi nition of 
familial isolated pituitary adenomas (FIPA). 
In 15–20% of FIPA patients, mutations in the 
 AIP gene can be found. As clinical treatment 
in FIPA kindreds with  AIP mutations and in 
MEN1 cases with pituitary adenomas can be 
challenging compared with sporadic cases, the 
issues of when and how best to screen subjects 
genetically, hormonally and radiologically 
have become increasingly prominent. 
 Introduction 
 Pituitary adenomas represent a diverse group of 
predominantly benign tumours whose compara-
tively high prevalence in general population con-
tinues to provoke signi fi cant interest among 
endocrinologists and neurosurgeons. According 
to the last report of the Primary Brain and Central 
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they are the third most common form of brain 
neoplasia comprising 12.7% of all brain tumours 
by histology type and the second most common 
entity (25.4%) in young adults (20–34 years). 
Historically there has been a controversy concern-
ing their prevalence in general population as 
autopsy and radiological series reported  fi gures 
for incidentally-found pituitary adenomas as high 
as 14.4 and 22.5% respectively (Ezzat et al.  2004 ) 
while some older epidemiological studies esti-
mated their prevalence rates as 19–28 cases per 
100,000 inhabitants (Davis et al.  2001 ) . Two 
recent community-based cross-sectional studies 
in the Belgian province of Liege (Daly et al. 
 2006b ) and in Banbury, UK (Fernandez et al. 
 2010 ) , however, suggest that clinically apparent 
pituitary adenomas may occur as frequently as 94 
and 77.6 cases per 100,000 people respectively. 
These results indicate that the true prevalence of 
clinically relevant pituitary adenomas may have 
been underestimated previously. 
 The majority of pituitary adenomas occur spo-
radically and only 5% arise in a familial setting; 
familial acromegaly has been described for well 
over a century (Erdheim  1903 ) . Hereditary pituitary 
adenomas develop as a part of the distinct endo-
crine tumour syndromes: Multiple Endocrine 
Neoplasia type 1 (MEN1) and Carney Complex 
(CNC). The culprit gene in MEN1,  MEN1 , was 
identi fi ed in 1997 (Chandrasekharappa et al. 
 1997 ) and by 2008 approximately 565 different 
mutations were reported (Lemos and Thakker 
 2008 ) . In 1985 Carney et al.  ( 1986 ) described a 
new multiple tumour syndrome (CNC) that pre-
sented infrequently with familial acromegaly. 
Genetic research has linked almost 70% of cases 
with Carney complex to mutations in the gene for 
type A regulatory subunit of protein kinase A 
(PRKAR1A) (Kirschner  2010 ) . By the end of 
1990s, however, signi fi cant numbers of patients 
had accumulated who had familial pituitary 
tumours without mutations in either  MEN1 or 
 PRKAR1A genes. A new condition, termed 
Familial Isolated Pituitary Adenomas (FIPA) was 
coined to describe these families (Valdes Socin 
et al.  2000 ) . Mutations in the  aryl hydrocarbon 
receptor interacting  protein ( AIP ) gene were 
reported in FIPA patients (Vierimaa et al.  2006 ) , 
but account for about 15–20% of all patients with 
this disorder; therefore the search for other 
genetic causes is still ongoing. 
 Multiple Endocrine Neoplasia 
Type 1 (Men 1) 
 Multiple endocrine neoplasia type 1 (MEN 1) is a 
rare autosomal dominant condition with high 
penetrance and no sex predominance. It is char-
acterized by the occurrence of primary hyper-
parathyroidism, enteropancreatic neuroendocrine 
tumours and pituitary adenomas; other associated 
non endocrine tumors can occur. Sporadic and 
familial forms have been described; the  fi rst 
presenting with pathology in at least two of the 
three principle endocrine glands and the second 
is de fi ned as a MEN 1 case plus a  fi rst degree 
relative with one of these three tumours. 
Parathyroid adenomas are usually the  fi rst clinical 
manifestation of the disorder and affect as many 
as 95% of patients by the age of 50 (Falchetti 
et al.  2008 ) . Diagnosed in 35–80% of patients, 
pancreatic islet cell tumours are the second most 
common presentation of MEN1 and are mostly 
characterized by excessive hormone production 
leading to marked clinical symptoms. Gastrinomas 
causing Zollinger-Ellison syndrome account for 
nearly a half of pancreatic lesions in MEN1 and 
due to multiple peptic ulcers and a large propor-
tion of malignant tumours they represent one of 
the major causes for mortality and morbidity in 
this condition (Marini et al.  2006 ) . The preva-
lence of pituitary tumours in MEN1 varies widely 
from 10 to 60% in the different studies and they 
are the  fi rst clinical manifestation of the disease 
in up to 25% of patients (Falchetti et al.  2008 ) . 
However, only 2.7% of pituitary adenomas can 
be attributed to MEN 1 (Scheithauer et al.  1987 ) . 
Pituitary pathology is much more prevalent in 
familial MEN 1 cases compared to non-familial 
ones. Also, women with MEN 1 have an increased 
predisposition to having a pituitary adenoma. 
Nearly all types of pituitary tumours have been 
reported, with prolactinomas being the most fre-
quent, but the proportions of prolactin-secreting, 
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GH-secreting, ACTH-secreting and non-functional 
adenomas remain similar in MEN 1 cases and 
sporadic populations (Verges et al.  2002 ) . 
Pituitary tumours in MEN 1, however, appear to 
be larger and more aggressive than their sporadic 
counterparts and macroadenomas comprise 
approximately 85% of them compared to only 
42% of non-MEN 1 pituitary adenomas. This is 
probably one of the reasons why MEN 1 pituitary 
tumours are more likely to cause compression 
related symptoms. This tendency for aggressive-
ness is especially well observed in MEN 1 
prolactinomas where the proportion of macroad-
enomas reaches 84% in contrast to the general 
population where microadenomas are the pre-
dominant prolactinoma phenotype (Daly et al. 
 2009 ) . Response to therapy is also signi fi cantly 
lower in MEN 1 related pituitary tumours as only 
42% of them achieve hormone normalization in 
contrast to sporadic functional pituitary adenomas 
where almost 90% of patients can be successfully 
treated (Verges et al.  2002 ) . Apart from these 
three main types of neoplasms, over 20 other 
endocrine and non-endocrine tumours have been 
described in association with MEN 1. These 
include the less common carcinoid tumours and 
adrenal cortical tumours, usually non-secreting, 
as well as various inactive benign lesions such as 
lipomas, facial angio fi bromas and collagenomas. 
 Genetic studies for loss of heterozigoty 
have linked the responsible gene to a locus on 
chromosome 11q13 (Larsson et al.  1988 ) . The 
gene itself was cloned several years later 
(Chandrasekharappa et al.  1997 ) and consists of 
10 exons, encoding a 610 amino acid protein, 
called menin.  MEN1 is generally considered to act 
as a tumour suppressor gene and its transcript – 
menin has been shown to interact with a variety 
of proteins that take part in transcriptional 
regulation, genome stability, cell proliferation 
and apoptosis. Localized predominantly in the 
nucleus, menin suppresses Jun- and NF- k B-
mediated transcriptional activation, participates 
in the regulation of transforming growth factor- b 
(TGF- b ) signaling pathways by interacting with 
Smad family of proteins, regulates the expres-
sion of cyclin-dependant kinase inhibitors genes 
p27 and p18 by being a component in histone 
methyltransferase complexes, inhibits cell 
proliferation through interacting with the activator 
of S-phase kinase (ASK), maintains stable gene 
expression by controlling genome stability and 
DNA replication and repair (Lemos and Thakker 
 2008 ) . Further more, numerous menin binding 
sites in chromatin were identi fi ed, many of them 
being not only within promoter regions, but also 
inside 3’ end of genes as well as introns. However, 
none of the numerous menin functions has been 
proven  critical in MEN1 tumorigenesis. A recent 
study demonstrated overexpression of transcrip-
tional factor HLXB9 in pancreatic islet cells in 
the absence of menin (Scacheri et al.  2006 ) , 
implicating the possibility that preferential 
targeting of speci fi c genes by menin in endocrine 
tissue may explain the tendency for endocrine 
tumour formation. A pituitary speci fi c function 
of menin is the interaction with activin – a nega-
tive regulator of prolactin, growth hormone and 
corticotropine secretion and pituitary cell prolif-
eration, mediated through the inhibition of  Pit-1 
gene expression (Hendy et al.  2005 ) . 
 Mutations in  MEN1 gene are spread throughout 
the whole coding sequence and include 41% 
frameshift deletions, 23% nonsense mutations, 
20% missense mutations, 9% splice-site muta-
tions, 6% in-frame deletions and 1% whole gene 
deletions (Lemos and Thakker  2008 ) . The major-
ity of them lead to synthesis of truncated protein. 
The impact of the lack of menin on MEN 1 tum-
origenesis has been studied in specially developed 
knockout mouse models. Homozigous animals 
( MEN1 −/− ) die early in embryonic phase with 
severe developmental defects in many organs 
while heterozygous mice ( MEN1 +/− ) develop 
parathyroid adenomas and carcinomas, pancreatic 
islet cells tumours, pituitary adenomas and various 
other types of neoplasia, thus providing a model 
for human MEN 1 disease. Pituitary pathology in 
these animals is con fi ned mainly to prolactinomas 
and somatotropinomas with a large proportion of 
malignant cases (Lemos and Thakker  2008 ) . 
 So far no evident genotype-phenotype correla-
tions have been observed although few kindreds 
with prevailing prolactinomas have been reported in 
Canada and Tasmania. Mutations in  MEN1 are also 
detected in one third of sporadic enteropancreatic 
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tumours and 20% of sporadic parathyroid 
adenomas but they seem to be extremely rare in 
sporadic pituitary adenomas although loss of 
heterozygoty in locus 11q13 has been proven for 
up to 30% of them (Daly et al.  2009 ) . 
 Multiple Endocrine Neoplasia 
Type 4 (Men 4) 
 Despite the large number of identi fi ed mutations 
in coding regions of  MEN 1 gene, DNA tests still 
fail to detect anomalies in more than 20% of 
patients with clinical characteristics of the disease. 
This may be due to mutations within introns or 
promoter regions or may also imply the involve-
ment of other genes in the development of 
MEN 1-like conditions. Recently a mutation in 
 CDNK1B gene, coding cycline-dependant kinase 
inhibitor p27 Kip1 , was identi fi ed in rats with MEN 
1-like symptoms (Pellegata et al.  2006 ) . The animals 
presented with numerous neuroendocrine tumours 
like pheochromocytoma, medullary thyroid car-
cinoma, parathyroid adenomas, pancreatic 
hyperplasia and pituitary adenomas. In humans 
 CDNK1B gene is located on chromosome 12p13 
and its product p27 Kip1 plays an important role in 
cell cycle regulation by inhibiting cyclin/CDK 
complexes. Interestingly, pituitary adenomas 
originating from the intermediate lobe are the 
only tumours that develop spontaneously in 
homozygous p27 Kip1−/− mice. Although mutations 
in human  CDKN1B gene are con fi rmed in only 
 fi ve families the condition was accepted as a new 
syndrome and called MEN 4. The  fi rst registered 
case was documented in a German kindred exhib-
iting familial acromegaly, primary hyperparathy-
roidism, renal angiomyolipoma and testicular 
cancer among various members. Genetic testing 
revealed a nonsense mutation in  CDKN1B gene 
in the absence of any detectable pathology in 
 MEN1 gene (Pellegata et al.  2006 ) . Soon after, a 
heterozygous germline frameshift mutation of 
 CDKN1B gene was reported in another MEN1-
like case, negative for  MEN1 mutations, – a 
Dutch female patient with small-cell cervical 
carcinoma, ACTH-secreting pitui-tary adenoma 
and hyperparathyroidism. More recently, three 
novel mutations were identi fi ed in MEN1-like 
cases presenting with parathyroid and other 
endocrine tumours but without pituitary lesions 
(Agarwal et al.  2009 ) . Mutations in CDKN1B 
gene are, however, found in less than 3% of 
patients with presumable MEN1 phenotypes, 
negative for MEN1 muatations, which suggests 
that other genetic factors may also be involved. 
(Pellegata et al.  2006 ; Agarwal et al.  2009 ) . 
 Carney Complex 
 Carney Complex (CNC) is another autosomal 
dominant condition that is associated though 
infrequently with familial pituitary pathology, 
mainly acromegaly. The disease is characterized 
by spotty skin pigmentations, myxomas, endo-
crine hyperactivity and schwannomas and since 
the description of the  fi rst cohort of patients in 
1985 (Carney et al.  1986 ) more than 500 patients 
have been reported in the largest database 
(Boikos and Stratakis  2007 ) . Approximately 
70% of cases with CNC present in a familial trait 
with slight female predominance. Benign skin 
lesions are the most common clinical manifesta-
tion of the disease and include lentigenes, cuta-
neous or mucosal myxomas, blue nevi and 
café-au-lait spots. Cardiac myxomas are the 
most frequent non-cutaneous lesions in CNC 
and account for more than a half of the disease-
speci fi c mortality. Endocrine abnormalities are 
observed in approximately a third of CNC 
patients and are mainly due to Cushing’s syn-
drome caused by primary pigmented nodular 
adrenocortical disease (PPNAD). Less common 
endocrine presentations include large cell calci-
fying sertoli cell tumours (LCCSCTs) and benign 
or malignant thyroid nodules (Boikos and 
Stratakis  2007 ) . Pituitary adenomas occur with 
an incidence of 10–12% of CNC patients and 
usually cause acromegaly or gigantism depend-
ing on the age of onset but at least one family 
with prolactinomas has also been reported 
(Kirschner  2010 ) . A distinguishing feature of 
GH-secreting tumours in CNC is multifocal 
hyperplasia of somatomammotrope cells amidst 
normal pituitary tissue. This  fi nding, together with 
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the elevations in GH and IGF 1 levels as well as 
mild hyperprolactinemia that can be detected in 
almost 75% of patients, suggests that acro-
megaly in CNC may develop insidiously from 
pituitary hyperplasia to overt adenoma. 
 Inactivating mutations in the gene for type 
1A regulatory subunit of protein kinase A 
( PRKAR1A ), located on chromosome 17q22–24, 
have been identi fi ed in over 70% of patients 
with CNC. Unlike MEN 1, however, CNC is 
probably genetically heterogeneous as a second 
locus on chromosome 2p16 has been implicated 
although speci fi c genetic alterations still have to 
be con fi rmed in affected families (Boikos and 
Stratakis  2007 ) . As in MEN 1, no somatic muta-
tions in  PRKAR1A gene have been documented 
in sporadic pituitary tumours. Protein kinase A 
(PKA) is a cAMP-dependant protein kinase 
composed of two regulatory and two catalytic 
subunits and is a component of a wide scope of 
metabolic and regulatory pathways involved in 
cell proliferation, transcription and apoptosis. 
The majority of  PRKAR1A gene mutations lead 
to premature stop codon generation and subse-
quent nonsense mRNA degradation. The loss of 
type 1A regulatory subunits disrupts the balance 
in PKA tetramer formation and induces release 
of free catalytic subunits resulting in increased 
cAMP-dependant kinase activity in affected tis-
sues (Robinson-White et al.  2006 ) . In pituitary 
cells the stimulation of GHRH receptor by its 
ligand leads to GH synthesis and release through 
the PKA pathway and its speci fi c activation 
in CNC may result in GH hypersecretion in 
the absence of physiologic signals. Complete 
knockout of  PRKAR1A gene in mice severely 
impairs cardiac morphogenesis and is lethal 
during early embryogenesis while heterozygous 
 PRKAR1A  +/−  animals, despite exhibiting many 
of the tumour lesions observed in humans with 
CNC, fail to develop any signi fi cant pituitary 
pathology. Tissue-speci fi c ablation of  PRKAR1A 
gene in mice, however, induces gradual devel-
opment of pituitary tumours with biochemical 
features, quite similar to CNC-related acromeg-
aly in humans, e.g. GH hypersecretion with slow 
progression from hyperplasia to adenoma 
(Kirschner  2010 ) . 
 Familial Isolated Pituitary 
Adenomas (FIPA) 
 Familial isolated pituitary adenomas (FIPA) repre-
sent a recently de fi ned hereditary syndrome char-
acterized by familial occurrence of pituitary 
tumours of any functional type in the absence of 
clinical and genetic features of MEN 1 and CNC 
(Beckers and Daly  2007 ) . Since its  fi rst descrip-
tion at the end of the last century (Valdes Socin 
et al.  2000 ) active research and increased recogni-
tion has led to the identi fi cation of more than 200 
families with this disorder (Chahal et al.  2010 ) . 
However, FIPA is estimated to account only for 
2.5% of all pituitary tumours, a proportion similar 
to MEN 1 (Daly et al.  2006a ) . Genealogical data 
from affected kindreds indicates autosomal 
dominant mode of inheritance with incomplete 
penetrance. Tumour phenotype within individual 
FIPA families may present in homogeneous 
manner with all affected members exhibiting the 
same adenoma type, or heterogeneously when 
different pituitary tumours arise within the kindred. 
All functional types of pituitary tumours may be 
associated with this condition but prolactin- or 
GH-secreting adenomas are almost inevitably 
present in affected families. Prolactin-secreting 
adenomas are the most common phenotype and 
comprise about 40% of all FIPA tumours Sexual 
predisposition, age of presentation and proportion 
of microadenomas are similar to sporadic pro-
lactinomas. In heterogeneous FIPA families, how-
ever, they exhibit more aggressive behavior with 
signi fi cantly higher rates of suprasellar extension 
and cavernous sinus invasion. GH-secreting ade-
nomas account for 30% of FIPA tumours and 
somatoprolactinomas are responsible for another 
7% of them. They are equally distributed between 
homogeneous and heterogeneous families but, 
unlike FIPA prolactinomas, somatotropinomas are 
more aggressive when occurring in a homoge-
neous setting. In homogeneous FIPA, acromegaly 
is usually diagnosed 10 years earlier with tumours 
more frequently displaying extracellar growth 
compared to heterogeneous kindreds and sporadic 
populations (Beckers and Daly  2007 ) . Acromegaly 
in FIPA patients also appears to respond poorly to 
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somatostatin analogue therapy (Leontiou et al. 
 2008 ) . Non-secreting adenomas, predominantly 
associated with heterogeneous families, arise in 
13% of FIPA patients and are also characterized 
by more aggressive evolution, being diagnosed 
earlier and exhibiting more invasive properties 
than sporadic adenomas. Gonadotropinomas, 
corticotropinomas and thyreotropinomas account 
for 4, 4 and 1% of FIPA tumours respectively and 
are usually associated with other adenoma types 
in heterogeneous kindreds although individual 
families with homogeneous presentation have 
been reported (Beckers and Daly  2007 ) . 
 In 2006 a detailed genome-wide screening in 
search for potential genes involved in familial ade-
noma tumorigenesis implicated that inactivating 
mutations in the gene coding aryl hydrocarbon 
receptor interacting protein ( AIP ) could be respon-
sible for familial acromegaly and prolactinomas in 
large Finnish kindreds (Vierimaa et al.  2006 ) . Loss 
of heterozygoty at the  AIP locus in tumour tissue 
from affected patients indicates that  AIP gene may 
experience a tumour suppressor function. In the 
largest cohorts of FIPA patients mutations in  AIP 
gene can be found in approximately 22% of all 
cases and in 40% of families with acromegaly 
occurring in a homogeneous FIPA setting (Beckers 
and Daly,  2007; Chahal et al.  2010 ) . Though quite 
infrequently, patients with sporadic pituitary 
tumours also seem to harbour  AIP mutations 
with the majority of them having acromegaly. 
Within FIPA families,  AIP mutation carriers are 
signi fi cantly younger at diagnosis and tend to have 
larger tumours than patients with normal  AIP 
sequence (Daly et al.  2007 ) . Contrary to the overall 
female predominance in FIPA, they are mostly men 
(71%) and usually present with somatotropinomas 
or somatoprolactinomas (86%) (Cazabat et al. 
 2009 ) . There also exists some  discrepancy in terms 
of clinical characteristics and histology results in 
tumours positive for  AIP mutations as somatotropi-
nomas are stained not only for GH but in a third of 
cases for prolactin and infrequently for FSH 
(Beckers and Daly  2007 ) . 
 The  AIP gene is ubiquitously expressed in var-
ious tissues throughout the body and in normal 
pituitary it is associated with secretory granules 
in somatotrope and lactotrope cells. In sporadic 
pituitary adenomas, however,  AIP is expressed in 
all tumour types but in prolacatinomas, non-
secreting adenomas and corticotropinomas it 
can only be identi fi ed in the cytoplasm whereas 
in somatotropinomas it is localized within 
secretory vesicles (Leontiou et al.  2008 ) . The exact 
pathophysiological mechanisms that are involved 
in pituitary tumorigenesis caused by  AIP muta-
tions still remain unknown. Homozygous  AIP  −/− 
knockout mice develop severe cardiovascular 
abnormalities that are incompatible with life while 
heterozygotes (AIP +/− ) exhibit no pituitary pathol-
ogy. The gene itself consists of 6 exons and 
encodes a 330 aminoacid protein which C-terminal 
end is required for binding to the aryl hydrocar-
bon receptor (AhR).  This receptor acts as ligand-
inducible transcription factor and modulates 
cellular responses to various toxic environmental 
substances, such as dioxins (Beckers and Daly 
 2007 ) . In the absence of ligands the AhR couples 
to a dimer of the 90 kDa heat shock protein 
(HSP90), acting as chaperone, and AIP and p23 
proteins, acting as co-chaperons, to form a multi-
protein complex in the cytoplasm (Kazlauskas 
et al.  1999 ) . The activation of the complex by its 
xenobiotic ligand results in nuclear translocation 
where AhR binds to the aryl hydrocarbon receptor 
nuclear translocator (ARNT) and promotes the 
transcription of speci fi c genes coding various drug 
metabolizing enzymes as well as other proteins 
such as the cyclin dependant kinase inhibitor 
p27 Kip1 . The role of AIP in the regulation of AhR 
activity is not quite clear, but it seems to partici-
pate in the stabilization and the cytoplasmic 
retention of the complex by an yet unknown 
mechanism. Data on the effect of AhR activation 
on cell proliferation are controversial but recently 
it was shown that reduced AIP expression in 
pituitary adenomas, positive for AIP mutations, is 
associated with decreased AhR activity, suggesting 
an inhibitory function of AhR in pituitary tumori-
genesis (Jaffrain-Rea et al.  2009 ) . Further more, 
AIP overexpression in cell cultures including 
pituitary cell lines slows down cell proliferation 
rates (Leontiou et al.  2008 ) . Another possible 
pathophysiological link between AIP and pitui-
tary tumorigenesis lies in the interaction with two 
speci fi c types of phosphodiesterases – PDE4A5 
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and PDE2A. These enzymes inactivate cyclic 
nucleotides like cAMP by disrupting the phos-
phodiester bond in their molecules and thus they 
may participate in the regulation of the various 
signaling pathways utilizing cAMP as intracellu-
lar second messenger, including the GHRH recep-
tor cascade in pituitary cells. The interaction of 
AIP with PDE4A5, however, inhibits enzyme 
activity with resultant increase in cAMP concen-
tration and it currently remains unclear if a tumour 
suppressor effect can be achieved in this way as 
cAMP overproduction is usually associated with 
pro-oncogenic outcomes. Binding to PDE2A 
interrupts the nuclear translocation of the AhR 
complex possibly by local reduction in cAMP lev-
els (Oz fi rat and Korbonits  2010 ) . Very recently 
the tyrosine kinase receptor encoded by the  RET 
protooncogene was identi fi ed as a novel binding 
partner of AIP in pituitary cells. Depending on the 
presence or the absence of its speci fi c ligand – glial 
cell line-derived neurotropic factor (GDNF) – 
RET promotes cell growth and migration or 
induces apoptosis respectively. More over, the 
domain responsible for the proapoptotic activity 
is the same that is responsible for AIP interaction. 
This RET-AIP binding presumably prevents the 
formation of a complex between AIP and sur-
vivin – a recently recognized apoptosis inhibitor 
and cell cycle regulator. Without the stabilizing 
role of AIP, survivin is put to rapid degradation 
with consequent increase in apoptosis (Vargiolu 
et al.  2009 ) . In vitro studies, however, have failed 
to con fi rm that some missense AIP mutations 
could disrupt the association with RET (Chahal 
et al.  2010 ) and although it may be tempting to 
accept a more essential role of such interaction in 
pituitary tumorigenesis its true relevance remains 
ques tionable. Apart from stabilizing the AhR 
complex, AIP may also bind to a set of nuclear 
receptors including the peroxysome proliferator-
activated receptor  a (PPAR a ), the glucocorticoid 
receptor, and  b -thyroid hormone receptor 1 (TR b 1). 
Further more, it has been proposed a role in virus 
induced tumorigenesis as a potential partner of 
hepatitis B virus X antigen and Epstein-Barr virus-
encoded nuclear antigen 3 (EBNA-3)(Oz fi rat and 
Korbonits  2010 ) . The outcomes of these interac-
tions, however, still remain to be fully elucidated. 
 To date, more than 50 different mutations have 
been identi fi ed throughout the sequence of  AIP 
gene and approximately 70% of them disrupt the 
C-terminal end of AIP polypeptide chain that is 
essential for protein-protein interactions. Nonsense 
and frameshift mutations lead to premature stop 
codons with resultant truncated protein while mis-
sense mutations tend to affect the TPR domains and 
the terminal  a -helix. Several mutations like R304, 
R271 and R81 are reported in independent FIPA 
families from different centers indicating possible 
mutational hotspots in the  AIP gene while the Q14X 
mutation, though common in Finnish FIPA kin-
dreds, has not been identi fi ed elsewhere suggesting 
possible founder effect (Oz fi rat and Korbonits 
 2010 ) . So far no genotype-phenotype correlations 
have been reported in FIPA families harbouring AIP 
mutations although some observations may imply a 
less aggressive character for mutations with con-
served C-terminal part of AIP (Cazabat et al.  2009 ) . 
Families with marked heredity for pituitary tumours, 
however, may lack mutations in  AIP gene which is 
a strong indicator that other genetic disruptions may 
also be involved in FIPA development. 
 Management of Familial Pituitary 
Adenomas 
 Treatment of pituitary tumours that arise in famil-
ial setting practically does not differ from the 
management of sporadic adenomas in terms of 
indications and therapeutic approaches. Physicians 
should bear in mind, however, that pituitary tumours 
developing as a part of MEN 1 and FIPA syn-
dromes have more aggressive evolution, present 
earlier and often respond poorly to therapy. As 
MEN 1 has been recognized for quite some time 
consensus statements and guidelines for the inves-
tigation and management of this condition have 
been developed (Brandi et al.  2001 ) . Genetic test-
ing for mutations in  MEN 1 gene is warranted in 
patients who meet the clinical criteria for the 
disease and the identi fi cation of a mutation 
allows screening for carriers among the relatives. 
Mutation positive individuals should undergo 
annual biochemical assessment of prolactin, start-
ing from the age of 5, total serum calcium from 
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the age of 8 and gastrin from age 20 as well as 
periodic (every 3–5 years) imaging tests to screen 
for relevant tumours. Mutation negative relatives 
can be surely excluded from further follow-up. 
When no mutation could be identi fi ed in the index 
case it may be appropriate to consider a haplotype 
or linkage analysis in an investigational labora-
tory provided suf fi cient number of affected family 
members is available. Testing for mutations in 
 CDKN1B gene in MEN 1-like cases without  MEN 
1 mutations is still reserved only for research pur-
poses as MEN 4 seems to be extremely rare con-
dition. Similarly, patients meeting the diagnostic 
criteria for CNC should be tested for germline 
mutations in  PRKAR1A gene. Carriers should be 
followed-up for the different presentations of the 
syndrome and clinical, biochemical and imaging 
screening should be performed on a yearly basis. 
Regarding pituitary pathology, evaluation of GH, 
IGF 1 and prolactin secretion is appropriate. By 
de fi nition FIPA is diagnosed in patients with 
hereditary pituitary tumours in the absence of 
mutations of  MEN 1 and  PRKAR1A genes and as 
the number of reported families increase detailed 
family history is of essential importance in patients 
with pituitary adenomas. Although mutations of 
 AIP gene are observed in only 20% of cases 
genetic testing in at least one affected member 
may be valuable from a clinical aspect as patients 
with mutations are associated with more aggres-
sive disease. Identifying carriers among relatives 
is potentially bene fi cial for performing regular 
MRI and hormonal evaluation. In the absence of 
tumour on the imaging study surveillance may be 
carried on clinically and biochemically (IGF 1 and 
prolactin). Special attention should be paid to 
genetic counseling of FIPA patients and their 
relatives because of the relatively low prevalence 
of  AIP mutations and the uncertain degree of 
penetrance. Genetic screening among sporadic 
pituitary adenomas may not be warranted in unse-
lected cases but it may be considered in young 
patients with aggressive disease who are more 
likely to carry  AIP mutations. 
 In conclusion, familial presentation of pitu-
itary tumours although occurring in a small 
proportion of patients with pituitary adenoma 
provides a unique opportunity for investigation of 
genetic and molecular pathways of tumorigenesis. 
In recent years the scope of familial pituitary 
syndromes has expanded with the de fi nition of 
FIPA and MEN4 in addition to the well-described 
MEN1 and CNC. More over, modern technology 
has made possible not only the elucidation of 
culprit genetic defects behind these disorders but 
also presents an important tool for identifying 
at-risk individuals among affected families. The 
in-dept understanding of the speci fi c evolution 
and clinical characteristics of familial syndromes 
may provide basis for preclinical diagnosis, 
better prevention and appropriate management of 
individual patients. Still, much remains to be 
done, especially in FIPA where the majority of 
patients do not harbour  AIP mutations and may 
possibly have defects in yet unidenti fi ed genes. 
In addition, it is unclear whether FIPA patients 
have also predisposition for other endocrine or 
non-endocrine tumours which could expand its 
de fi nition beyond the pituitary. Further clinical 
studies in larger populations as well as the devel-
opment of appropriate experimental models may 
help elucidate these issues. 
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